Author:
Carles Joan,Chirivella Isabel,Climent Miguel Ángel,Gallardo Enrique,González del Alba Arancha,Maroto José Pablo,Mellado Begoña,García del Muro Francisco Xavier
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356(2), 115–124. Jan 11.
2. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., et al. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology, 27(20), 3312–3318. Jul 10.
3. Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A., & Wilt, T. (2005). Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, 1, CD001425.
4. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine, 356(22), 2271–2281. May 31.
5. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370(9605), 2103–2111. Dec 22.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献